clinical trial · NCT07174726
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
X-Linked Retinitis Pigmentosa (XLRP)Adeno-associated virus vector expressing a human RPGR gene
brief summary
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
started
Sep 10, 2025
primary completion
Jun 30, 2027
completion
Dec 15, 2030
last updated
Feb 19, 2026
detailed description
XLRP is a genetic (inherited) eye disease that affects cells in the retina (the lining of the back of the eye that detects light). It causes night blindness and gradual worsening of your vision.
The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol